Antimelanoma activity of 1,3,4-thiadiazolium mesoionics: A structure-activity relationship study

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 269-275

  Senff Ribeiro, Andrea ^a   Echevarria, Aurea ^b   Silva, Edson R ^b   Veiga, Silvio S ^a   Oliveira, Maria B M ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

1,3,4 thiadiazolium mesoionics; Anti melanoma activity; Structure activity study

Indexed keywords

1,3,4 THIADIAZOLIUM DERIVATIVE; AMPHOLYTE; ANTINEOPLASTIC AGENT; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH INHIBITORS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1842531964     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00012     Document Type: Article

References (34)

1. Moustafa MAA, Eisa HM. Synthesis and antimicrobial activity of 3-(substituted-phenyl)-sydnones. Arch Pharm 1991; 325:397-401.
2. Corell T, Pedersen SB, Lissau B, Moilanen E, Mëtsa-Ketelä T, Kankaanranta H, et al. Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems. Pol J Pharmacol 1994; 46:553-566.
3. Satyanarayana K, Rao MNA. Synthesis and antiinflammatory, analgesics and antipyretic testing of 4-[1-oxo-(3-substituted aryl)-2-propenyl]-3- phenylsydnones and of 3-[4-[3-(substituted aryl)-1-oxo-2-propenyl] phenyl] sydnones. J Pharm Sci 1995; 84:263-266.
4. Rehse K, Ciborski T, Müller B. Platelet aggregation inhibiting and anticoagulant effects of oligoamines. XXVII. Inhibition of leucocyte adherence to endothelium by oligoamine RE 1492C and the NO-donor RE 2047. Arch Pharm (Weinheim) 1995; 328:125-126.
5. Ollis WD, Ramsden CA. Meso-ionic compounds. Adv Heterocycl Chem 1976; 19:1-121.
6. Newton CG, Ramsden CA. Meso-ionic heterocycles. Tetrahedron 1982; 38:2965-3011.
7. Moura GLC, Simas AM, Miller J. Mesoionic rings as efficient asymmetric bridges for the design of compounds with large optical nonlinearities. Chem Phys Lett 1996; 257:639-646.
8. Cheung KK, Echevarria A, Galembeck S, Maciel MAM, Miller J, Rumjanek VM, et al. Mesoionic compounds 3. Structure of the hydrochloride of 5-(4-methoxyphenyl)-1,3,4-thiadiazolium-2-phenylamine. Acta Crystallogr 1992; 48:1471-1474.
9. Echevarria A, Galembeck SE, Maciel MAM, Miller J, Montanari CA, Rumjanek VM, et al. Reaction of aroyl chlorides with 1,4-diphenylthiosemicarbazide: formation of both 1,3,4-thiadiazolium-2-aminides and 1,3,4-thiadiazolium-2- thiolate. Heterocycl Commun 1996; 1:129-136.
10. Kier LB, Roche EB. Medicinal chemistry of the mesoionic compounds. J Pharm Sci 1967; 56:148-169.
11. Badachikar SV, Tikare RK, Puranik GS. Synthesis, reactions and biological activity of 3-[p-(N-methyl/ethyl-N-phenylcarbamoyl)] phenylsydnones. Indian J Chem 1986; 258:1079-1080.
12. Montanari CA, Beezer AE, Sandall JPB, Montanari MLC, Miller J, Giesbrecht AM. On the interaction of some mesoionic compounds with Saccharomyces cerevisae by biological microcalorimetry. Rev Microbiol 1992; 23:274-278.
13. Corell T, Pedersen SB, Lissau B, Moilanen E, Mëtsa-Ketelä T, Kankaanranta H, et al. Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems. Pol J Pharmacol 1994; 46:553-566.
14. Kankaanranta H, Rydell E, Peterson AS, Holm P, Moilanen E, Corell T, et al. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br J Pharm 1996; 117:401-406.
15. Shinzato TO, Grynberg N, Gomes RM, Echevarria A, Miller J. Antitumor activity of new mesoionic compounds against three murine tumors. Med Sci Res 1989; 17:865-866.
16. Grynberg N, Gomes R, Shinzato T, Echevarria A, Miller J. Some new aryl sydnones: effects on murine tumors. Anticancer Res 1992; 12:1025-1028.
17. Grynberg N, Santos AC, Echevarria A. Synthesis and in vivo antitumor activity of new heterocycles derivates of 1,3,4-thiadiazolium-2-aminide class. Anticancer Drugs 1997; 8:88-91.
18. Majid PA, DeFeyter PJF, VanderWall EE, Wardeh R, Ross JP. Molsidomine in the treatment of patients with angina pectoris. N Engl J Med 1980; 302:1-6.
19. Rudolph W, Derschinger J. Clinical comparison of nitrates and sydnonimines. Eur Heart J 1991; 12:33-41.
20. Rehse K, Konig P. New NO-donors with antithrombotic and vasodilating activities. XII. Mesoionic oxatriazoles and related monocyclic nitrosohydrazine derivatives. Arch Pharm 1995; 328:137-142.
21. Hogg N, Darley-Usmar VM, Wilson MT, Moncada S. Production of hydroxyl radicals from simultaneous generation of superoxide and nitric oxide. Biochem J 1992; 281:419-424.
22. 13C NMR chemical shifts of substituted 1,3,4-thiadiazolium salts. Magn Reson Chem 2001; 39:182-186.
23. Silva EF, Canto-Cavalheiro MM, Braz VR, Cysne-Finkelstein L, Leon L, Echevarria A. Synthesis and biological evaluation of new 1,3,4-thiadiazolium-2- phenylamine derivatives against Leishmania amazonensis promastigotes and amastigotes. Eur J Med Chem 2002; 37:979-984.
24. 2. J Med Chem 1993; 36:2041-2043.
25. Schavartzapel AJ, Zhong L, Docampo R, Rodrigues JB, Gros EG. Design, synthesis, and biological evaluation of new growth inhibitors of Trypanosoma cruzi (epimastigotes). J Med Chem 1997; 40:2314-2322.
26. Cadena SMSC, Carnieri EGS, Echevarria A, Oliveira MBM. Effect of MI-D, a new mesoionic compound, on energy-linked functions of rat liver mitochondria. FEBS Lett 1998; 440:46-50.
27. Cadena SMSC, Carnieri EGS, Echevarria A, Oliveira MBM. Interference of MI-D, a new mesoionic compound, on artificial and native membranes. Cell Biochem Funct 2002; 20:31-37.
28. Senff-Ribeiro A, Echevarria A, Silva EF, Veiga SS, Oliveira MBM. Effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on B16-F10 murine melanoma. Melanoma Res 2003; 13: in press.
29. Phillips HJ. Dye exclusions tests for cell viability. In: Kruse JR, Patterson JRMK (editors): Tissue Culture, Methods and Applications. New York: Academic Press; 1973, pp. 406-408.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
31. Blaschek W, Käsbauer J, Kraus J, Franz G. Phythium aphanidermatum: culture, cell-wall composition, and isolation and structure of antitumor storage and solubilised cell-wall (1 → 3),(1 → 6)-β-d-glucans. Carbohydr Res 1992; 231:293-307.
32. Ren DL, Wang JZ, Noda H, Amano H, Ogawa S. The effects of an algal polysaccharide from Gloiopeltis tenax on transplantable tumors and immune activities in mice. Planta Med 1995; 61:120-125.
33. Kubinyi H, Abraham U. Practical problems in PLS analyses. In: Kubinyi H (editor): 3D QSAR in Drug Design. Theory, Methods and Applications. Leiden: ESCOM; 1993, pp. 717-728.
34. Hansh C, Leo A, Hoekman D. Exploring QSAR: Hydrophobic, Eletronic and Steric Constants. Washington, DC: American Chemical Society; 1995.